Back to search results

CBD and Cannabis Effects Study

This outpatient study is looking at how different doses of Cannabidiol (CBD) affect the way people experience cannabis and how it might help with pain. Researchers will give participants either a medium or higher dose of active CBD, or a placebo (inactive) CBD, for 14 days. Participants will also receive active inhaled cannabis or placebo inhaled cannabis on specific study days. The study aims to understand how CBD changes how much people like cannabis and their willingness to purchase it. You may be able to join if you are an English-speaking adult between 18 and 55, not currently seeking treatment for cannabis use, and meet other health criteria. The study is currently unclear on its recruitment status and plans to enroll 23 participants.

Study design
This interventional study plans to enroll 23 participants. It compares the effects of different doses of Cannabidiol (CBD) and cannabis.
What's involved
Participants will receive oral CBD for 14 days and inhaled cannabis on Days 1, 7, and 14. Measurements will be taken on these days, including before and after drug administration for about 8 hours per session.
Compensation
Not stated in the trial record.
Follow-up
Measurements for drug liking and cannabis purchase behavior are taken on Days 1, 7, and 14.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07434895

Repeated CBD Administration and Cannabis Outcomes

Recruiting
EARLY_PHASE1Ages 18–55InterventionalBasic science
Hannah Harris
~23 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Cannabidiol, Medium DoseCannabidiol, Higher DoseActive Inhaled CannabisPlacebo CannabidiolPlacebo Inhaled Cannabis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline-Subject-Related Outcome-VAS Drug Liking
Measured over Days 1 (baseline), 7, 14, prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).
+1 more outcome measured

Conditions

Cannabis
Abuse Liability
Experimental Pain in Healthy Human Participants

Explore related trials

Cannabis misuse

Where it's being run

1 sites across 1 states
Kentucky1

Study leadership

  • Hannah M Harris, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

Paul A Nuzzo, M.A.
[email protected]
859-323-0002
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

English-speaking, literate adults,
Male or female,
Between the ages of 18-55,
Body Mass Index from 18.5-32.0 kg/m2,
Not currently seeking treatment for cannabis or drug use,
Able to provide written informed consent and perform all study procedures,
If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.

Exclusion

Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \[e.g., asthma, COPD\]),
Current or past history of major psychiatric disorder that would limit ability to participate in the study,
Use of cannabis exclusively for medical reasons (no recreational use reported),
Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
Clinically significant abnormal ECG (as determined by study physician/cardiologist),
Clinically significant abnormal laboratory findings,
History of seizure disorder,
Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).

What this trial measures

  • Change from Baseline-Subject-Related Outcome-VAS Drug LikingDays 1 (baseline), 7, 14, prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).

    Participants rated their subjective drug liking on a standardized VAS scale (0 to 100). These Scores will indicate how participants are feeling at that moment, including questions on mood, physical symptoms, and drug effects. Low scores mean little to no drug liking. Higher scores mean greater drug liking. Raw data transformed to peak scores.

  • Change from Baseline-Marijuana Purchase Task: ElasticityDays 1 (baseline), 7, 14, measured ~3 hours post cannabis administration.

    Behavioral economic demand for cannabis: how much a participant values cannabis as its "price" (cost, effort, or availability) increases. Participants indicate how much marijuana they would buy and consume at increasing, hypothetical prices. This outcome describes how sensitive marijuana consumption is to price changes and how quickly demand decreases as marijuana becomes more expensive.